Nakamoto Inc.
Financial ServicesNASDAQ:NAKA · NASDAQ Global Market
-$0.15 today
Vol 0.25M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.2%
avg 145.8%
ROIC
-27.2%
avg -153.4%
ROA
-7.1%
avg -97.5%
Analysis
ROA is currently the strongest return metric at -7.1% versus its period average of -97.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Amanda Fabiano | Chief Operating Officer | $1.02M | — | 39 | $4.14M | 23.76% |
Tyler Matthew Evans | Chief Investment Officer & Director | $626,993.00 | — | 34 | $20.85M | 119.83% |
David Forrest Bailey | Chairman & Chief Executive Officer | $572,919.00 | — | 35 | $3.18M | 18.25% |
Timothy Pickett | Chief Medical Officer & Director | $490,906.00 | — | 47 | $136,618.00 | 0.79% |
Kevin Zhang | Head of Asia | — | — | — | — | — |
John Dalton | Chief Accounting Officer & Controller | — | — | 44 | $1.69M | 9.69% |
Steven Lubka | Vice President of Investor Relations | — | — | — | — | — |
Andrew Creighton | Chief Commercial Officer | — | — | 53 | $1.69M | 9.69% |
Kyle Simon | General Counsel & Secretary | — | — | — | — | — |
Teresa S. Gendron | CFO & Treasurer | — | — | 56 | $2.62M | 15.08% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$992,628.14
Sells
0
$0.00
Net Sentiment
+$992,628.14
Net buying
Most Active
Bailey David F
5 transactions
Analysis
Insiders reported 5 buys worth $992,628.14 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $992,628.14. Bailey David F was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -21.7% | +197.6% (3yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -21.7% over three years. Forward estimates point to Revenue at +197.6% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.88B
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Delcath Systems, Inc.
NASDAQ:DCTH
$404.59M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
Who manages NAKA?
Nakamoto Inc. (NAKA) lists 10 active executives. The top listed executive is Kevin Zhang, Head of Asia.
Are NAKA insiders buying or selling?
Recent insider activity shows net buying of $3.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.